HomeCompareIGXT vs RYLD

IGXT vs RYLD: Dividend Comparison 2026

IGXT yields 1176.47% · RYLD yields 12.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IGXT wins by $78814195.16M in total portfolio value
10 years
IGXT
IGXT
● Live price
1176.47%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78814195.20M
Annual income
$67,523,701,253,088.38
Full IGXT calculator →
RYLD
RYLD
● Live price
12.39%
Share price
$14.64
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.3K
Annual income
$2,682.98
Full RYLD calculator →

Portfolio growth — IGXT vs RYLD

📍 IGXT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIGXTRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IGXT + RYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IGXT pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IGXT
Annual income on $10K today (after 15% tax)
$100,000.00/yr
After 10yr DRIP, annual income (after tax)
$57,395,146,065,125.13/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,053.44/yr
After 10yr DRIP, annual income (after tax)
$2,280.53/yr
At 15% tax rate, IGXT beats the other by $57,395,146,062,844.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IGXT + RYLD for your $10,000?

IGXT: 50%RYLD: 50%
100% RYLD50/50100% IGXT
Portfolio after 10yr
$39407097.62M
Annual income
$33,761,850,627,885.68/yr
Blended yield
85.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IGXT right now

IGXT
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-23.8
Piotroski
4/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IGXT buys
0
RYLD buys
0
No recent congressional trades found for IGXT or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIGXTRYLD
Forward yield1176.47%12.39%
Annual dividend / share$2.00$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$78814195.20M$45.3K
Annual income after 10y$67,523,701,253,088.38$2,682.98
Total dividends collected$77969765.27M$19.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IGXT vs RYLD ($10,000, DRIP)

YearIGXT PortfolioIGXT Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$128,347$117,647.06$11,939$1,239.34+$116.4KIGXT
2$1,548,514$1,411,182.61$14,158$1,382.89+$1.53MIGXT
3$17,569,052$15,912,142.01$16,682$1,532.59+$17.55MIGXT
4$187,523,354$168,724,468.35$19,537$1,687.64+$187.50MIGXT
5$1,883,716,681$1,683,066,692.55$22,752$1,847.20+$1883.69MIGXT
6$17,816,329,317$15,800,752,468.33$26,355$2,010.43+$17816.30MIGXT
7$158,731,384,105$139,667,911,735.60$30,376$2,176.45+$158731.35MIGXT
8$1,332,782,916,056$1,162,940,335,063.89$34,847$2,344.43+$1332782.88MIGXT
9$10,551,863,503,163$9,125,785,782,982.70$39,800$2,513.54+$10551863.46MIGXT
10$78,814,195,201,473$67,523,701,253,088.38$45,269$2,682.98+$78814195.16MIGXT

IGXT vs RYLD: Complete Analysis 2026

IGXTStock

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Full IGXT Calculator →

RYLDETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this IGXT vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IGXT vs SCHDIGXT vs JEPIIGXT vs OIGXT vs KOIGXT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.